OrbusNeich Medical Group Holdings (FRA:Q8T) ROCE %: 12.53% (As of Dec. 2025)


FRA:Q8T OrbusNeich Medical Group Holdings Ltd FRA:Q8T
96 GF Score
Price €0.37
GF Value €0.47
! 2 Warning Signs
View Full Analysis

What is OrbusNeich Medical Group Holdings ROCE %?

OrbusNeich Medical Group Holdings FRA:Q8T -3.17% 96 ROCE % is 12.53% as of Dec. 2025. GuruFocus rates FRA:Q8T with a GF Score™ of 96/100 and a GF Value™ of €0.47. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OrbusNeich Medical Group Holdings's annualized ROCE % for the quarter that ended in Dec. 2025 was 12.53%.

OrbusNeich Medical Group Holdings  (FRA:Q8T) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OrbusNeich Medical Group Holdings ROCE % Related Terms

OrbusNeich Medical Group Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for OrbusNeich Medical Group Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OrbusNeich Medical Group Holdings ROCE % Chart

OrbusNeich Medical Group Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 2.89 8.25 13.99 11.22 10.90

OrbusNeich Medical Group Holdings Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.91 11.43 11.03 9.75 12.53
FRA:Q8T
96GF Score
OrbusNeich Medical Group Holdings Ltd FRA:Q8T
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OrbusNeich Medical Group Holdings ROCE % Calculation

OrbusNeich Medical Group Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=40.355/( ( (411.615 - 29.34) + (386.785 - 28.408) )/ 2 )
=40.355/( (382.275+358.377)/ 2 )
=40.355/370.326
=10.90 %

OrbusNeich Medical Group Holdings's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=45.034/( ( (386.51 - 25.791) + (386.785 - 28.408) )/ 2 )
=45.034/( ( 360.719 + 358.377 )/ 2 )
=45.034/359.548
=12.53 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.53% mean?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a ROCE % of 12.53% as of Dec. 2025.
Is OrbusNeich Medical Group Holdings' ROCE % too high?
OrbusNeich Medical Group Holdings' current ROCE % is 12.53%. The Medical Devices & Instruments industry median ROCE % is 2.23. OrbusNeich Medical Group Holdings' value of 12.53% is 461.9% above this industry median. Overall, OrbusNeich Medical Group Holdings has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does OrbusNeich Medical Group Holdings' ROCE % compare to ISRG and BDX?
OrbusNeich Medical Group Holdings' ROCE % of 12.53% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. OrbusNeich Medical Group Holdings' value of 12.53% is 461.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OrbusNeich Medical Group Holdings's current ROCE % of 12.53% is 461.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OrbusNeich Medical Group Holdings's current ROCE % is 12.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrbusNeich Medical Group Holdings stock overvalued right now?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a current ROCE % of 12.53%. The stock's GF Value™ is €0.47, compared to a current price of €0.37 — trading 22.1% below its estimated fair value. The current ROCE % is 12.53% and 461.9% above the Medical Devices & Instruments industry median of 2.23. OrbusNeich Medical Group Holdings' overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For OrbusNeich Medical Group Holdings (FRA:Q8T), the current ROCE % is 12.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OrbusNeich Medical Group Holdings (FRA:Q8T) Overvalued in 2026?

Based on GuruFocus' analysis, OrbusNeich Medical Group Holdings stock appears to be undervalued. The current stock price of €0.37 is trading 22.1% below its estimated GF Value™ of €0.47.

Key valuation signals for FRA:Q8T:

  • ROCE %: 12.53%
  • GF Value™: €0.47 vs. price of €0.37 (22.1% below fair value)
  • GF Score™: 96/100 with 2 warning signs
  • Industry Position: 461.9% above the Medical Devices & Instruments median

No single metric tells the full story. See the FRA:Q8T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OrbusNeich Medical Group Holdings Business Description

Other Exchanges 06929:Hong Kong
Address 3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG
OrbusNeich Medical Group Holdings Ltd is an investment holding company. The Company principally engaged in the manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases. The group has only one operating segment. The company has presence in APAC, EMEA, Japan, United States, The PRC, and Others of which majority of revenue comes from APAC.
96GF Score

Get the complete analysis for FRA:Q8T

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price
€0.47
GF Value